SCHEMBL13348591

SCHEMBL13348591

CCOC(=O)c1ncccc1OC(C)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.53
MEN1 O00255 1/20 0.46
GABRP O00591 1/20 0.46
GABRD O14764 1/20 0.46
MAPT P10636 1/20 0.46
GABRA1 P14867 1/20 0.46
GABRB1 P18505 1/20 0.46
GABRG2 P18507 1/20 0.46
GABRB3 P28472 1/20 0.46
GABRA5 P31644 1/20 0.46
GABRA3 P34903 1/20 0.46
GABRA2 P47869 1/20 0.46
GABRB2 P47870 1/20 0.46
GABRA4 P48169 1/20 0.46
GABRE P78334 1/20 0.46
KMT2A Q03164 1/20 0.46
GABRA6 Q16445 1/20 0.46
GABRG1 Q8N1C3 1/20 0.46
GABRG3 Q99928 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1707917 0.87 KDM4E (0.53) BRD4MEN1GABRPGABRDMAPT
SCHEMBL5268656 0.86 BRD4 (0.53) BRD4MEN1GABRPGABRDMAPT
SCHEMBL30852245 0.86 BRD4 (0.53) BRD4MEN1GABRPGABRDMAPT
SCHEMBL31471103 0.83 BRD4 (0.60) BRD4MEN1KMT2AKDM4ETDP2
SCHEMBL27492257 0.82 BRD4 (0.58) BRD4MAPTTDP2PDE4ACYP1A2
SCHEMBL13348761 0.79 CYP1A2 (0.42) MEN1GABRPGABRDMAPTGABRA1
SCHEMBL7267932 0.79 BRD4 (0.56) BRD4TDP1KDM4ETDP2PDE4A
SCHEMBL13313473 0.79 BRD4 (0.56) BRD4TDP1KDM4ETDP2PDE4A
SCHEMBL1514835 0.78 BRD4 (0.55) BRD4MEN1MAPTKMT2AKDM4E
SCHEMBL29604747 0.78 BRD4 (0.55) BRD4MEN1MAPTKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160346-A1 NEUROLOGICALLY ACTIVE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2010-06-24 US disclosed
US-7692011-B2 8-hydroxy and 8-mercapto quinazolinones PRANA BIOTECHNOLOGY LIMITED (AU) 2010-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160346-A1 NEUROLOGICALLY ACTIVE COMPOUNDS ACHE, PSEN1, PSEN2 BRD4 1797/4885MEN1 1991/4885GABRP 697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.